account_id none on file
legal_name Protagenic Therapeutics, Inc.\new
ticker PTIX
cik 1022899
domain protagenic.com
linkedin_company_url https://www.linkedin.com/company/protagenics-therapeutics-inc/
entry_point_account_id none on file
name Protagenic Therapeutics Inc.
exchange OTC
sector Health Care
hq New York, NY, United States
sector index/company/sector/health-care/
calls 0 filings 9 executives 3 family 0
why_nownone on file
callsnone on file
filings
Office Space The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr.
filing / Aug 19, 2026 / receipt
Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does
filing / Aug 19, 2026 / receipt
Company is working a restructuring plan and related accounting and disclosures. Such procedures are being completed with Audit Committee
filing / Aug 19, 2026 / receipt
August 8, 2025, the Board of Directors (the “Board”) approved a focused restructuring plan (the “Restructuring Plan”) to transition to a virtual operating model and concentrate capital on the Company’s highest-priority clinical program(s).
filing / Aug 14, 2026 / receipt
Workforce reductions also included the certain roles primarily associated with preclinical operations, regulatory affairs, and intellectual property functions.
filing / Aug 14, 2026 / receipt
The Company leases office space for its principal executive office located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
filing / Aug 14, 2026 / receipt
Company leases office space from a company in which an officer has an ownership interest. The lease is believed to be at or below market
filing / Aug 14, 2026 / receipt
If we are not able to raise needed funding under acceptable terms or at all, then we will have to reduce expenses, including the possible options of curtailing operations, abandoning opportunities, licensing or selling off assets, reducing costs to a point where clinical development or other progress is impaired, or ceasing operations entirely.
filing / Aug 14, 2026 / receipt
These cost reduction initiatives could decrease the coverage and price that we receive for our products in the future and could seriously harm our business.
filing / Aug 14, 2026 / receipt
executives
| Barrett Evans | President and Chief Executive Officer | - | receipt |
| Gil Klier | director | - | receipt |
| Thomas Plotts | Interim Chief Financial Officer | - | receipt |
familynone on file
upcomingnone on file
changes
| 2025-05-19 | President and Chief Executive Officer, appointed | sec_8k |
| 2010-08-17 | Chief Executive Officer, departed | sec_8k |
| 2009-12-21 | Chief Financial Officer, departed | sec_8k |
| 2009-12-21 | Interim Chief Financial Officer, appointed | sec_8k |
| 2009-10-07 | Chief Executive Officer, departed | sec_8k |
| 2009-10-07 | Chief Marketing Officer, departed | sec_8k |
| 2009-10-07 | Interim Chief Executive Officer, appointed | sec_8k |
| 2008-03-19 | Chief Operating Officer, departed | sec_8k |
| 2007-08-14 | director, appointed | sec_8k |
| 2007-01-26 | director, departed | sec_8k |
| 2006-10-30 | Director, departed | sec_8k |
| 2006-10-30 | President, departed | sec_8k |
mcp_package_hint
slug protagenic-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$